The international ARIA guidelines on the pharmacological management of allergic rhinitis now include Dymista^®.³

The original 2010 ARIA guidelines were the first evidence-based recommendations in allergy to follow the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. In the GRADE system, recommendations are classed as “strong” or “conditional”, depending on the guideline panel’s confidence that following the recommendation would be more beneficial than harmful to patients.

The ARIA guideline panel included allergists, ear-nose-throat specialists, pulmonologists, general practitioners, and paediatricians.

The guidelines are aimed primarily at primary care clinicians, school nurses, pharmacists, specialists in allergy and clinical immunology, general internists managing patients with allergic rhinitis, and paediatricians.

Dymista^® is indicated for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.⁴

• Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
• Scottish Medicine Consortium (SMC). Available at https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
• Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-958.
• Dymista^®. Summary of product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450/smpc.
  Last accessed: November 2018.